Pharmacogenetics and Depression: A Critical Perspective

키워드

참고문헌 (89)

1. Global Burden of Disease Study Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013", Lancet, 386, pp.743~800 (2015)
2. Malhi GS, "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders", Aust N Z J Psychiatry, 49, pp.1087~1206 (2015)
3. Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological Treatments", Can J Psychiatry, 61, pp.540~560 (2016)
4. Taylor D, "The Maudsley Prescribing Guidelines in Psychiatry" (2018), Wiley-Blackwell
5. Trivedi MH, "Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D : implications for clinical practice", Am J Psychiatry, 163, pp.28~40 (2006)
6. Souery D, "Switching antidepressant class does not improve response or remission in treatment-resistant depression", J Clin Psychopharmacol, 31, pp.512~516 (2011)
7. Singh AB, "Antidepressant pharmacogenetics", Curr Opin Psychiatry, 27, pp.43~51 (2014)
8. O’Reilly RL, "Pharmacogenetic response to antidepressants in a multicase family with affective disorder", Biol Psychiatry, 36, pp.467~471 (1994)
9. Franchini L, "Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees", J Psychiatr Res, 32, pp.255~259 (1998)
10. Tansey KE, "Contribution of common genetic variants to antidepressant response", Biol Psychiatry, 73, pp.679~682 (2013)
11. Bassett AS, "Copy number variations in schizophrenia : critical review and new perspectives on concepts of genetics and disease", Am J Psychiatry, 167, pp.899~914 (2010)
12. Dong S, "De novo insertions and deletions of predominantly paternal origin are associated with autism spectrum disorder", Cell Rep, 9, pp.16~23 (2014)
13. O’Dushlaine C, "Rare copy number variation in treatment-resistant major depressive disorder", Biol Psychiatry, 76, pp.536~541 (2014)
14. Tansey KE, "Copy number variants and therapeutic response to antidepressant medication in major depressive disorder", Pharmacogenomics J, 14, pp.395~399 (2014)
15. Niitsu T, "Pharmacogenetics in major depression : a comprehensive meta-analysis", Prog Neuropsychopharmacol Biol Psychiatry, 45, pp.183~194 (2013)
16. Border R, "No support for historical candidate gene or candidate gene-by-interaction hypotheses for major depression across multiple large samples", Am J Psychiatry, 176, pp.376~387 (2019)
17. Hicks JK, "Clinical Pharmacogenetics Implementation Consortium(CPIC)guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake Iinhibitors", Clin Pharmacol Ther, 98, pp.127~134 (2015)
18. Bank PCD, "Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the Dutch pharmacogenetics working froup", Clin Pharmacol Ther, 103, pp.599~618 (2018)
19. Porcelli S, "Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism", Expert Opin Drug Metab Toxicol, 7, pp.1101~1115 (2011)
20. Hicks JK, "Clinical pharmacogenetics implementation consortium guideline(CPIC)for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants : 2016 update", Clin Pharmacol Ther, 102, pp.37~44 (2017)
21. Fabbri C, "Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects : meta-analysis of data from genomewide association studies", Eur Neuropsychopharmacol, 28, pp.945~954 (2018)
22. Schizophrenia Working Group of the Psychiatric Genomics Consortium, "Biological insights from 108 schizophrenia-associated genetic loci", Nature, 511, pp.421~427 (2014)
23. Fabbri C, "Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples", Br J Psychiatry, 214, pp.36~41 (2019)
24. Gadad BS, "Association of novel ALX4 gene polymorphisms with antidepressant treatment response : findings from the CO-MED trial", Mol Neuropsychiatry, 4, pp.7~19 (2018)
25. Guo W, "Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression", Transl Psychiatry, 8, pp.280~ (2018)
26. Wigmore EM, "Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP", Pharmacogenomics J (2019)
27. Maciukiewicz M, "Genome-wide association studies of placebo and duloxetine response in major depressive disorder", Pharmacogenomics J, 18, pp.406~412 (2018)
28. Cocchi E, "Genome-wide association study of antidepressant response : involvement of the inorganic cation transmembrane transporter activity pathway", BMC Psychiatry, 16, pp.106~ (2016)
29. Garriock HA, "A genomewide association study of citalopram response in major depressive disorder", Biol Psychiatry, 67, pp.133~138 (2010)
30. Ising M, "A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression", Arch Gen Psychiatry, 66, pp.966~975 (2009)
31. Uher R, "Genome-wide pharmacogenetics of antidepressant response in the GENDEP project", Am J Psychiatry, 167, pp.555~564 (2010)
32. Li QS, "Analysis of 23andMe antidepressant efficacy survey data : implication of circadian rhythm and neuroplasticity in bupropion response", Transl Psychiatry, 6, pp.e889~ (2016)
33. Biernacka JM, "The International SSRI Pharmacogenomics Consortium(ISPC) : a genome-wide association study of antidepressant treatment response", Transl Psychiatry, 5, pp.e553~ (2015)
34. Sasayama D, "Possible association of CUX1 gene polymorphisms with antidepressant response in major depressive disorder", Pharmacogenomics J, 13, pp.354~358 (2013)
35. Tansey KE, "Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder : a genome-wide analysis of individual-level data and a meta-analysis", PLoS Med, 9, pp.e1001326~ (2012)
36. GENDEP Investigators, "STAR*D Investigators Common genetic variation and antidepressant efficacy in major depressive disorder : a meta-analysis of three genome-wide pharmacogenetic studies", Am J Psychiatry, 170, pp.207~217 (2013)
37. Kayserili H, "ALX4 dysfunction disrupts craniofacial and epidermal development", Hum Mol Genet, 18, pp.4357~4366 (2009)
38. Myung W, "A genomewide association study of antidepressant response in Koreans", Transl Psychiatry, 5, pp.e633~ (2015)
39. Oksenberg N, "The role of AUTS2 in neurodevelopment and human evolution", Trends Genet, 29, pp.600~608 (2013)
40. Hamshere ML, "Genetic utility of broadly defined bipolar schizoaffective disorder as a diagnostic concept", Br J Psychiatry, 195, pp.23~29 (2009)
41. Hattori E, "Preliminary genome-wide association study of bipolar disorder in the Japanese population", Am J Med Genet B Neuropsychiatr Genet, 150B, pp.1110~1117 (2009)
42. Tammiste A, "Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression", J Psychopharmacol, 27, pp.915~920 (2013)
43. Wong ML, "Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans", Am J Psychiatry, 171, pp.1297~1309 (2014)
44. Uher R, "Association of a brain methylation site with clinical outcomes in depression does not replicate across populations", Am J Psychiatry, 172, pp.395~397 (2015)
45. McCarthy S, "A reference panel of 64, 976 haplotypes for genotype imputation", Nat Genet, 48, pp.1279~1283 (2016)
46. Manolio TA, "Finding the missing heritability of complex diseases", Nature, 461, pp.747~753 (2009)
47. Hunter AM, "A genome-wide association study of a sustained pattern of antidepressant response", J Psychiatr Res, 47, pp.1157~1165 (2013)
48. Fabbri C, "Neuronal cell adhesion genes and antidepressant response in three independent samples", Pharmacogenomics J, 15, pp.538~548 (2015)
49. Tanti A, "Neurogenesis along the septo-temporal axis of the hippocampus: are depression and the action of antidepressants regionspecific?", Neuroscience, 252, pp.234~252 (2013)
50. Fabbri C, "PPP3CC gene : a putative modulator of antidepressant response through the B-cell receptor signaling pathway", Pharmacogenomics J, 14, pp.463~472 (2014)
51. Strawbridge R, "Inflammation and clinical response to treatment in depression : a meta-analysis", Eur Neuropsychopharmacol, 25, pp.1532~1543 (2015)
52. Eyre H, "Neuroplastic changes in depression : a role for the immune system", Psychoneuroendocrinology, 37, pp.1397~1416 (2012)
53. Garcia-Campos MA, "Pathway analysis : state of the art", Front Physiol, 6, pp.383~ (2015)
54. Garcia-Gonzalez J, "Pharmacogenetics of antidepressant response : a polygenic approach", Prog Neuropsychopharmacol Biol Psychiatry, 75, pp.128~134 (2017)
55. Ward J, "Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response : meta-analysis of three treatment cohorts", PLoS One, 13, pp.e0203896~ (2018)
56. Zwicker A, "Genetic disposition to inflammation and response to antidepressants in major depressive disorder", J Psychiatr Res, 105, pp.17~22 (2018)
57. Shi J, "Winner’s curse correction and variable thresholding improve performance of polygenic risk modeling based on genome-wide association study summary-level data", PLoS Genet, 12, pp.e1006493~ (2016)
58. Fabbri C, "Is a polygenic predictor of antidepressant response a possibility?", Pharmacogenomics, 18, pp.749~752 (2017)
59. Nelson MR, "The support of human genetic evidence for approved drug indications", Nat Genet, 47, pp.856~860 (2015)
60. Nosengo N, "Can you teach old drugs new tricks?", Nature, 534, pp.314~316 (2016)
61. Smietana K, "Trends in clinical success rates", Nat Rev Drug Discov, 15, pp.379~380 (2016)
62. Pritchard JE, "Enhancing the promise of drug repositioning through genetics", Front Pharmacol, 8, pp.896~ (2017)
63. So HC, "Translating GWAS findings into therapies for depression and anxiety disorders: gene-set analyses reveal enrichment of psychiatric drug classes and implications for drug repositioning", Psychol Med, pp.1~17 (2018)
64. So HC, "Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry", Nat Neurosci, 20, pp.1342~1349 (2017)
65. Wong BC, "Differential associations of depression-related phenotypes with cardiometabolic risks : polygenic analyses and exploring shared genetic variants and pathways", Depress Anxiety, 36, pp.330~344 (2019)
66. "Table of Pharmacogenomic Biomarkers in Drug Labeling"[URL]
67. Fabbri C, "Pharmacogenetic tests to guide drug treatment in depression : comparison of the available testing kits and clinical trials", Prog Neuropsychopharmacol Biol Psychiatry, 86, pp.36~44 (2018)
68. Winner JG, "Combinatorial versus individual gene pharmacogenomic testing in mental health : a perspective on context and implications on clinical utility", Yale J Biol Med, 88, pp.375~382 (2015)
69. Winner JG, "A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder", Discov Med, 16, pp.219~227 (2013)
70. Ajeet B. Singh, "Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report", Clinical Psychopharmacology and Neuroscience, 13(2), pp.150~156 (2015), 대한정신약물학회
71. Perez V, "Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder : results of a randomized, double-blind clinical trial", BMC Psychiatry, 17, pp.250~ (2017)
72. Bradley P, "Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety : a randomized clinical trial demonstrating clinical utility", J Psychiatr Res, 96, pp.100~107 (2018)
73. Greden JF, "Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial : a large, patient-and rater-blinded, randomized, controlled study", J Psychiatr Res, 111, pp.59~67 (2019)
74. Elliott LS, "Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients : a prospective pilot randomized controlled trial", PLoS One, 12, pp.e0170905~ (2017)
75. Stamm TJ, "The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression", J Psychopharmacol, 30, pp.40~47 (2016)
76. Bousman CA, "Commercial pharmacogenetic-based decision-support tools in psychiatry", Lancet Psychiatry, 3, pp.585~590 (2016)
77. "European Network of Centres for Pharmacoepidemiology and Pharmacovigilance-Pharmacoepidemiology Erasmus University"[URL]
78. van der Wouden CH, "Implementing pharmacogenomics in Europe : design and implementation strategy of the ubiquitous pharmacogenomics consortium", Clin Pharmacol Ther, 101, pp.341~358 (2017)
79. Maciukiewicz M, "GWAS-based machine learning approach to predict duloxetine response in major depressive disorder", J Psychiatr Res, 99, pp.62~68 (2018)
80. Lin E, "A deep learning approach for predicting antidepressant response in major depression using clinical and genetic biomarkers", Front Psychiatry, 9, pp.290~ (2018)
81. Fabbri C, "Pleiotropic genes in psychiatry : calcium channels and the stress-related FKBP5 gene in antidepressant resistance", Prog Neuropsychopharmacol Biol Psychiatry, 81, pp.203~210 (2018)
82. "National Human Genome Research Institute DNA Sequencing Costs"[URL]
83. 홍은표, "Sample Size and Statistical Power Calculation in Genetic Association Studies", Genomics & Informatics, 10(2), pp.117~122 (2012), 한국유전체학회[DOI]
84. Converge consortium, "Sparse whole-genome sequencing identifies two loci for major depressive disorder", Nature, 523, pp.588~591 (2015)
85. American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders" (2013), American Psychiatric Association Publishing Inc
86. World Health Organization, "International Statistical Classification of Diseases and Related Health Problems" (2018), American Medical Association Press
87. Simmons JM, "The NIMH Research Domain Criteria(RDoC)Project : implications for genetics research", Mamm Genome, 25, pp.23~31 (2014)
88. Thompson C, "Psychiatrist attitudes towards pharmacogenetic testing, direct-to-consumer genetic testing, and integrating genetic counseling into psychiatric patient care", Psychiatry Res, 226, pp.68~72 (2015)
89. Walden LM, "Physicians’ opinions following pharmacogenetic testing for psychotropic medication", Psychiatry Res, 229, pp.913~918 (2015)

관련 논문AI추천